The Challenges in Biomarker Testing in Gastroesophageal Cancer / cancer, esmo 2026, ESMO 26, gastroesophageal cancer, Maria Maddalena ...
Beyond Science, It’s the People Who Make ESMO Special / Amalya Sargsyan, Arpi Asminian, cancer, Emad Shash, ESMO, esmo 2026, ...
What Should Oncologists Know About mRNA Cancer Vaccines? / cancer, cancer vaccines, ESMO, esmo 2026, ESMO 26, Menna Fouda, OncoDaily, Oncology ...
On July 9, 2026, FDA approved isatuximab-irfc (Sarclisa Escena, Sanofi Aventis) for subcutaneous injection in multiple myeloma, extending to all currently approved IV isatuximab indications: In ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
OncoDaily Grand Rounds at ESMO 2026: Key Discussions and Clinical Perspectives on Bladder Cancer, Part 1 ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
OptiTROP-Lung04 (NCT05870319), a pivotal phase 3 trial presented by Prof. Li Zhang (Guangzhou, China) at the ESMO Congress 2025, evaluated the efficacy and safety of the novel TROP2-directed ...
At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...
CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results